PDCD1 and neoplasm: Indeed, PD-1/PD-L1 blockade administered concomitantly with hypofractionated radiotherapy improved tumour control, compared to radiotherapy or ICPI alone, and generated sustained CD8 T cell responses and immunological memory (103) while simultaneously reducing immune suppression by myeloid-derived suppressor cells (MDSCs) (105).